Sudeep Pharma Q1 FY27 earnings call on Aug 5, 2026 at 11 AM

What the company has scheduled

Sudeep Pharma Limited has scheduled an earnings conference call with analysts and investors on Wednesday, August 5, 2026, at 11:00 AM IST. The discussion is set to focus on the company’s operational and financial performance for the quarter ended June 30, 2026 (Q1FY27). The event is positioned as a forum for stakeholders to review the latest quarterly outcomes and raise questions on the company’s strategic direction. The company’s filing states the intimation is being made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The notice in the material is dated July 27, 2026. It is issued by Dimple Mehta, Company Secretary and Compliance Officer of Sudeep Pharma Limited.

Compliance context and why the call matters

Under SEBI’s disclosure framework, such scheduled calls help ensure broader access to information for market participants. For investors, the Q1FY27 call matters because it signals that the June-quarter results are ready for discussion and dissemination. The filing itself does not provide specific reported figures such as revenue or net profit for Q1FY27. Still, it confirms that the company will address performance for the quarter ended June 30, 2026. The call is also relevant for investors tracking management commentary, especially around execution priorities and near-term operating conditions. As with other results-season calls, the Q&A portion often becomes the main source of clarifications on segment trends, demand conditions, and operational developments.

Host, call leader, and who represents Sudeep Pharma

Nuvama Wealth Management is hosting the conference call. The material mentions Mr. Archit Joshi of Nuvama Wealth Management Ltd. as the call leader. On the company side, the filing lists senior management participation and specifically names Sujit Bhayani, Managing Director, as a representative for the call. The presence of top management typically indicates that investors can expect an overview of quarter performance and responses to analyst questions. The invitation also includes participation access details for multiple geographies, including India, the USA, the UK, Singapore, and Hong Kong.

Dial-in access across regions

Participants can join through dedicated dial-in lines provided in the invite. The material lists two dial-in numbers for India (Mumbai) and toll-free numbers for select overseas regions.

Alternatively, investors may register and access the call via the link referenced in the annexure of the original filing, which is also stated to be available on the company’s investor relations website.

What is known about the Q1FY27 results timeline

The material indicates that Sudeep Pharma’s Q1FY27 results are expected in the July to August 2026 window, in line with the broader NSE and BSE results season for the quarter ending June 2026. It also notes that the scheduling of the earnings call confirms Q1FY27 results have been finalized and are ready for dissemination. Separately, the material includes a note that the trading window was closed from 1 July 2026 until 48 hours after the Q1FY27 results. While the filing does not state a specific results date, the combination of an earnings call schedule and the referenced results-season window provides a near-term timeframe for investors watching for the formal outcome.

Estimates and reference base cited in the material

Alongside the earnings call schedule, the provided material includes a Q1FY27 preview with estimate ranges, as well as the prior-year quarter base used for comparison. It cites a trailing-growth framework applied to a Q1 FY26 base of ₹130 crore revenue and ₹31 crore net profit, using a year-on-year growth signal referenced from Q4 FY26. It also provides a Q1 FY27 estimated range for revenue and PAT.

The same material also cites a shorter-horizon range of ₹885-954 over a 3-6 month horizon, contingent on the Q1FY27 results print matching or beating the trailing growth trend. These are estimates referenced in the text and are not presented as company guidance.

Stock snapshots and valuation metrics referenced

The material contains multiple market snapshots for Sudeep Pharma shares. One section cites a current market price (CMP) of ₹868, with a market capitalisation of ₹9,786 crore and a price-to-earnings multiple of 56.1. Another section lists a price of ₹780, a market cap of ₹7.3K crore, and a P/E ratio of 46.5. A separate snapshot mentions current price ₹809 with market cap ₹9,140 crore, stock P/E 52.9, book value ₹78.2, ROCE 28.1%, and ROE 25.2%, along with high/low of ₹883/₹524 and dividend yield of 0.00%.

Given these varying data points, investors typically reconcile valuation and market data using a single timestamped source around the results and call date. The earnings call can serve as an anchor event around which market participants update models and re-check multiples based on the latest reported numbers.

Company background and operating focus mentioned

The material describes Sudeep Pharma Limited as a manufacturer of pharmaceutical excipients, food-grade minerals, and specialty nutrition ingredients, serving over 100 countries, and notes that the company was incorporated in 1989. It also references a successful IPO listing on BSE and NSE on 28 November 2025. On business direction, the text states that the Pharma Food Nutrition (PFN) segment is expected to grow faster than the 10% achieved in FY26 in both FY27 and FY28, and that FY27 is expected to mark an inflection point with continued momentum in PFN and specialty ingredients verticals. It also notes that in the FY26 earnings call there was no explicit mention of new fundraising plans through debt or equity.

Capex and project milestone cited: Dahej battery materials

One specific operational milestone referenced is a battery materials project at Dahej. The text states Phase 1 capacity is 25,000 metric tons per year, with commissioning by April 2027. While this is outside the June-quarter reporting period, investors may look for any commentary on timelines, execution progress, and capex phasing when management addresses strategy during results-related interactions.

What investors may listen for on August 5

Based on the stated agenda, the call is intended to cover operational and financial performance for Q1FY27, followed by investor queries. With estimates in the public domain, investors often compare reported revenue and PAT against the cited ranges of ₹142-163 crore revenue and ₹30-38 crore PAT for Q1FY27. Market participants may also track management commentary on PFN growth expectations, specialty ingredients momentum, and progress on the Dahej battery materials project timeline. Any clarifications around results-season timing, the trading window, and next milestones can also be relevant for shareholders.

Key takeaways

Sudeep Pharma’s earnings call on August 5, 2026 at 11:00 AM IST is a scheduled forum to discuss Q1FY27 performance for the quarter ended June 30, 2026. The call is hosted by Nuvama Wealth Management and led by Archit Joshi, with senior management participation including Managing Director Sujit Bhayani. The company’s filing is made under Regulation 30 of SEBI Listing Regulations, and the notice is dated July 27, 2026. Investors will track the call alongside the July-August 2026 results-season window and any updates related to growth expectations and the Dahej project commissioning timeline stated as April 2027.